Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA6 | P23280 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA4 | P22748 | 3/20 | 0.52 |
| ▸ | CA5A | P35218 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | F13A1 | P00488 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | THPO | P40225 | 2/20 | 0.52 |
| ▸ | CASP2 | P42575 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18825662 | 0.96 | CA12 (0.50) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL27722730 | 0.75 | CA12 (0.81) | CA12CA6CA7CA9CA14 | |
| SCHEMBL9834009 | 0.72 | CA12 (0.52) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL4189337 | 0.72 | CA12 (0.87) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL30446193 | 0.72 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL26132507 | 0.72 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL288720 | 0.72 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL14965 | 0.72 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL8514287 | 0.72 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Hydrochloric Acid SCHEMBL28862282 | 0.71 | LMNA (0.58) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055489-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| US-20250000942-A1 | PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION | PRINCE BIOTECH, LLC | 2025-01-02 | — | — | US | disclosed |
| CN-118980553-A | Size-based separation of dissociated fixed tissue | 文塔纳医疗系统公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-110520735-B | Size-based separation of dissociated fixed tissue | 文塔纳医疗系统公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240210288-A1 | Representative Diagnostics | VENTANA MED SYST INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11959838-B2 | Representative diagnostics | VENTANA MEDICAL SYSTEMS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240077391-A1 | SIZE-BASED SEPARATION OF DISSOCIATED FIXED TISSUES | VENTANA MED SYST INC (US) | 2024-03-07 | — | — | US | disclosed |
| US-11768137-B2 | Size-based separation of dissociated fixed tissues | VENTANA MEDICAL SYSTEMS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230125630-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | UNIV MARYLAND (US) | 2023-04-27 | — | — | US | disclosed |
| US-6294136-B1 | SYSTEM COMPRISING SINGLE NUCLEIC ACID MOLECULE ELONGATED AND FIXED ALONG ITS LENGTH ONTO SOLID PLANAR SURFACE TO BE INDIVIDUALLY ANALYZABLE AND ACCESSIBLE FOR ENZYMATIC AND/OR HYBRIDIZATION REACTIONS, IMAGING DEVICE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-09-25 | — | — | US | disclosed |
| EP-1058562-A1 | COMPOSITIONS AND METHODS OF TREATING TUMORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6147198-A | NUCLEOTIDE SEQUENCES ELONGATED AND FIXED LENGTHWISE ON A SURFACE; FOR USE AS DIAGNOSTIC TOOLS DURING SEQUENCING AND GENOME ANALYSIS | NEW YORK UNIVERSITY (US) | 2000-11-14 | — | — | US | disclosed |
| WO-1999044645-A1 | COMPOSITIONS AND METHODS OF TREATING TUMORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-09-10 | — | — | WO | disclosed |
| EP-0871640-A1 | METHODS FOR MEASURING PHYSICAL CHARACTERISTICS OF NUCLEIC ACIDS BY MICROSCOPIC IMAGING | NEW YORK UNIVERSITY (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5720928-A | Image processing and analysis of individual nucleic acid molecules | NEW YORK UNIVERSITY (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1997031107-A2 | HUMAN SERUM LECTIN - INDUCED APOPTOSIS AND METHOD FOR DETECTING APOPTOSIS | COLES JOHN G (CA) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997011691-A1 | TREATMENT OF HUMAN PROSTATE CANCER WITH SPERMINE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1997-04-03 | — | — | WO | disclosed |
| WO-1996031522-A1 | METHODS FOR MEASURING PHYSICAL CHARACTERISTICS OF NUCLEIC ACIDS BY MICROSCOPIC IMAGING | NEW YORK UNIVERSITY (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125630-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | PHOSPHO1, PLCG2, PLCG1 | CA12 154/4885CA6 413/4885CA7 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.